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ABSTRACT 
 
Calcium phosphate cements (CPCs) are hydraulic cements. These are formed by a 
combination of one or more calcium orthophosphate powders. Calcium orthophosphates have 
been studied as bone re-pair materials for the last 80 years. Calcium phosphate cement (CPC) 
self-hardens to form hydroxyapatite, having excellent osteoconductivity and bone-
replacement capability. The present study was aimed at preparation of alpha tricalcium 
phosphate and Si doped alpha tricalcium phosphate and studying the effect of addition of 
glass fibers into them. The physicochemical and mechanical properties of α-tricalcium 
phosphate (α-TCP) cement and Si doped α-TCP were studied. α-TCP was prepared by solid 
state sintering of CaCO3, CaHPO4 and Si doped α-TCP powders were synthesized by reacting 
mixtures of CaCO3, CaHPO4, and SiO2(TEOS). Setting time, phase composition, hydrolysis 
conversion rate, microstructure, and diametral tensile strength (DTS)  of  undoped CPC and 
Si-doped  CPC were studied and compared. Both initial and final setting time of the 
developed cement was delayed because of Si addition. Crystalline phases of HA (JCPDS 9-
432), α-TCP (JCPDS 29-359) and β-TCP (JCPDS 9-169) were detected in the X-ray 
diffraction (XRD) pattern after setting and immersion in SBF for 0 hours to 10 days. The 
intensities of the α-TCP peaks at 22.2° (201) and 24.1° (161,-331) decreased when the time 
of immersion in SBF increased from 0 hours to10 days, due to its transformation into HA. Si 
doped CPC showed little slower rate of conversion into HA phase as compared to undoped 
CPC. The SEM image of the microstructure of cement showed better compactness and 
greater crystal entanglement in undoped CPC as compared to Si-doped CPC. This lower 
porosity and greater compactness in the microstructure attributes to greater DTS values 
observed in undoped CPC. Addition of 10 wt % of e-glass fiber into Si-doped α-TCP 
increased the mechanical strength of CPC as the fibers could make the structure compact and 
provide reinforcement. 
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1. INTRODUCTION 
 
1.1  What is Bone Cement 
According to IUPAC bone cement is defined as “ Synthetic, self-curing organic or inorganic 
material used to fill up a cavity or to create a mechanical fixation”. Bone cement is used for 
fixation of prosthesis to the living bone in orthopaedic operations. It is also commonly known 
as PMMA (polymethylmethacrylate). It is constituted of mainly two components: (i)A 
Polymer (i.e. powder) and (ii) A Monomer (i.e. liquid). The above two components are in 
turn made up of from a mixture of different ingredients that determine the unique 
characteristics of the bone cement.  
Bone cement to be considered effective should be durable over a period of time and should be 
able to withstand compressive stresses, bending stresses and transverse loads. As lesser 
porosity results in better mechanical strength, property of the bone cement should be such 
that lesser air gets entrapped into it due to mixing technique and/or due to its chemical 
composition. 
Artificial joints can be successfully transplanted using bone cement. The bone cement is used 
to fill the free space between the prosthesis (i.e., the artificial joints) and the bone. Human hip 
is acted on by approximately 10-12 times the body weight. Hence the bone cement must 
provide elasticity so that it can absorb the forces acting on the hips to ensure that the artificial 
implant remains in place over a long period. 
 
1.2 Calcium Phosphate Cement 
CPCs were first discovered in the 1980s by Brown and Chow and Le Geros et al. The first 
commercial CPC products were introduced in the 1990s for treatment of fractures and 
maxillo-facial defects.  
Calcium phosphates have been used by the biomedical and medical communities for several 
years
[2]
.It eliminates the donor site pain as in the case of autografts or possible infection in the 
case of xenografts and allografts.  
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Calcium phosphate cements are used as synthetic bone grafts. It provides several advantages 
like biocompatibility, excellent bioactivity, osteoconductivity, injectability, resorbality and 
their ability to form a direct bond with bone. 
Calcium phosphate cement (CPC) self-hardens to form hydroxyapatite which is the principle 
mineral component of bone. Calcium Phosphate cement can be easily implanted by using 
simple injection method or by other manual techniques for a variety of applications. Upon 
implantation CPC sets quickly under normal physiological conditions. It does not release any 
heat as it sets. However, CPCs also have some drawbacks such as poor mechanical 
performance, and lower strength due to its intrinsic porosity. 
 
1.3  Classification of Calcium Phosphate Cement 
 CPCs can be classified according to the end products developed namely (i) precipitated 
hydroxyapatite (HA) or (ii) brushite (DCPD). Hydroxyapatite is the most stable calcium 
phosphate at pH>4.2 and brushite at pH<4.2. 
In Apatite cement setting reaction, a poorly precipitated crystalline HA and/or CDHA is 
formed as the end product. These reactions are carried out in an aqueous environment and 
have low crystallinity. These are much similar to biological apatite of bones and teeth. This 
similarity in properties are believed to be responsible for their excellent in vivo resorption 
characteristics.  
Brushite cements form DCPD as their major end-product of the setting reaction. Brushite 
cements set by the acid-base reaction. During setting, the paste of brushite cement is always 
acidic. Acidic nature is required due to the following reasons (i) easier and faster preparation, 
(ii) better control of the chemical composition and reactivity, (iii) improved physio-chemical 
properties, such as longer setting times and larger tensile strengths due to a higher 
homogeneity. However, there are chances that the more acidic environment might reduce the 
biocompatibility of the cement formulation, due to low pH values during setting. 
  CPCs can also be classified depending upon the number of components. CPC’s can either be 
monocomponent or multicomponent.  
In monocomponent  CPCs,  a single calcium phosphate compound such as alpha tricalcium 
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phosphate (α-TCP) hydrolyses to CDHA without varying the Ca/P ratio  
3α-Ca3(PO4)2 + H2O  Ca9(HPO4)(PO4)5(OH) 
In multicomponent CPCs two or more calcium phosphates, some of acidic nature and  others 
of basic character, set following an acid–base reaction. 
Apatitic cement: 2Ca4(PO4)2O + 2CaHPO4 Ca10(PO4)6(OH)2 
Brushitic cement: 3Ca3(PO4)2 + Ca(H2PO4)2.H2O + 7H2O  4CaHPO4.2H2O 
The basic component is generally tetracalcium phosphate (TTCP), and the acidic component 
can either be dicalcium phosphate anhydrous (DCPA) or dicalcium phosphate dihydrate 
(DCPD). The Ca/P ratio of the final HA depends on the ratio between TTCP and the acidic 
component. 
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Figure 1: Classification of Calcium Phosphate Cement 
[3] 
1.4 Injectable calcium phosphate ceramic
 
Hydroxyapatite  is also known as Hydroxylapatite (HA). It is a naturally 
occurring mineral form of calcium apatite (Ca5(PO4)3(OH)). It is usually written as 
Ca10(PO4)6(OH)2 to denote the two entities of its crystal unit cell. Hydroxyapatite is 
the hydroxyl end member of the complex apatite group. It has a hexagonal crystal structure. 
Pure hydroxylapatite powder is white in colour. Naturally occurring apatites can, however, be 
brown, yellow, or green.
 
Hydroxyapatite is the major natural building block of bone and teeth. Bone cements, 
comprising of calcium and phosphate precursors in an aqueous solution, initially forms a 
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paste and then hardens into hydroxyapatite bone cement. These are useful in fixing fractures 
and bone defects.  
Hydroxyapatite is chemically similar to the mineral component of bones and hard tissues in 
mammals. Hydroxyapatite has a calcium to phosphorous ratio of approximately 1.67 which is 
generally the same as the calcium phosphate ratio in natural bone structures. It is amongst the  
few materials that are bioactive, i.e.,  they will support bone ingrowth and osteointegration. 
This justifies their  use in orthopedic, dental and maxillofacial applications. 
The chemical nature of hydroxyapatite makes it susceptible to substitution. Thus non-
stoichiometric hydroxyapatites may also exist. The most common substitutions include 
carbonate, fluoride and chloride substitutions for hydroxyl groups. Defects can also exist due 
to formation of deficient hydroxyapatites. Dense hydroxyapatite ceramics possess the 
following features. 
•        The ability to integrate in bone structures and support bone ingrowth, without breaking 
down or dissolving (i.e. it is bioactive). 
•        Hydroxyapatite is a thermally unstable compound. Depending on its stoichiometry it 
decomposes at temperature of about 800-1200°C. 
 •        Dense hydroxyapatite does not have ample mechanical strength to withstand load 
bearing applications for a long period. 
Autogenous bone graft is generally used for reconstruction of bone defects and provides 
mechanical integrity to the skeleton system of the patient. However, bone reconstruction by 
autograft suffers from certain disadvantages for example, (i) need for a second surgery at the 
donor site, (ii) limited availability of shape of the bone required to be grafted, (iii) resorption 
of the bone graft 
[4-6]
. 
Recently to reduce or eliminate bone grafting method injectable systems have been developed 
that can mould to the shape of bone cavity and can polymerize when injected in situ. Such 
systems render advantages such as lesser (i) time requirement to carry out the surgical 
operation, (ii) damage due to lesser muscle retraction, (iii) scars,(iv) post-operative pain. 
Poly(methyl methacrylate) (PMMA) is the most commonly used injectable bone cement. But 
factors such as its non degradability, high temperature requirement for curing can cause cell 
injury of the surrounding tissue 
[7]
. 
In such conditions calcium phosphate cement (CPC) serves as an alternative injectable 
material. Injectability of CPC is required for the minimal invasive applications like, spinal 
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applications, vertebroplasty, bone void filling in closed fracture sites and the reinforcement of 
osteoporotic. CPC self-hardens to form hydroxyapatite. 
Hardening: Self-setting calcium orthophosphate formulations are formed by mixing 
amorphous and/or crystalline calcium orthophosphate powder(s) with an aqueous solution 
such as distilled water, phosphate-buffered saline (PBS), aqueous solutions of sodium 
orthophosphate, orthophosphoric acid, citric acid, sodium silicate, magnesium hydro-
orthophosphate or  simulated body fluid (SBF). After the calcium orthophosphate powder(s) 
and the solution are mixed together, a viscous and moldable paste is formed that sets to a firm 
mass within a few minutes. When the paste becomes sufficiently stiff, it is introduced into a 
defect, where it hardens in situ within the operating theatre.  
CPCs set as a result of a dissolution and precipitation process. The cement is considered to be 
set when it can resist a given mechanical load applied onto its surface.The entanglement of 
the precipitated crystals is responsible for cement hardening unlike acrylic bone cements, 
which harden due to polymerization reaction. 
 
1.5  Properties::   
CPCs provide 
1. Self-setting ability in vivo . 
2. Good injectability that allows cement implantation by minimally invasive surgical 
techniques, thus reducing damages caused by traditional surgical techniques. 
3. Good osteoconductivity and occasional osteoinductivity.  
4. Can be replaced by newly formed bone after a period of time referred to as  
(osteotransductivity). 
 
1.6 Advantages and Disadvantages:: 
Some of the advantages of CPCs are listed below:: 
1) Moldability to perfectly fit the implant site, which assures good bone-material contact, 
even in geometrically complex defects. 
2) Excellent biocompatibility and bioactivity.  
3) No toxicity. 
4) Low cost.  
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5) Ease of preparation and handling.  
6) Setting at body temperature 
7) Can be used to deliver antibiotics, anti-inflammatory drugs, growth factors, morpho-
genic proteins 
CPCs also render following disadvantages: 
1) Mechanical weakness: limited use due to potential collapse of material followed by 
soft tissue formation instead of bone formation (loaded areas). Until cements with 
adequate shear strength are available, most complex fractures that can be repaired with 
cement also will require metal supports. 
2) Can be washed out from surgical defect if excess of blood flows.  
3) Lack of macroporosity (especially inter-connected pores), which prevents fast bone 
ingrowth and the cements degrade layer-by-layer from the outside to the inside only.  
4) The in vivo biodegradation of many formulations is slower than the growth rate of a 
newly forming bone  
 
1.7  Applications:: 
 It is used in orthopaedic, dental and maxillofacial applications 
 Calcium Phosphate Cement can be used to anchor artificial joints (hip joints, knee 
joints, shoulder and elbow joints) 
 Repair of periodontal defects 
 Augmentation of alveolar bone 
 Sinus lifts 
 Tooth replacement 
 Repair of large bone defects caused by tumors [8-14]. They are also used as scaffolds in 
tissue engineering for bone or dentin regeneration 
[14-18]
. 
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2. LITERATURE REVIEW 
 
CPCs were first discovered in the 1980s by Brown and Chow and LeGeros et al.. Studies on 
the use of calcium phosphates for bone defect repair appeared in the scientific literature as 
early as in 1920 The first commercial CPC products were introduced in the 1990s for 
treatment of fractures and maxillo-facial defects. CPCs were then used as efficient drug 
carriers between its inherent porosity. 
In 1920, Albee and Morrison used “triple calcium phosphate” as stimulus for bone growth. 
The results indicated rapid bone growth and union in the bone deficient site. Then the next 
generation calcium phosphate cement materials such as ready-to-use injectable CPC, fiber 
reinforced (FRCPC), calcium phosphate-containing polymeric scaffold sets having greater 
efficacies and applications were produced
[1]
. Considering the on going researches on CPCs, 
replacement of many autografts currently in use by CPC type materials in future would not be 
an unrealistic goal. 
Calcium orthophosphates have been used as bone repair materials for the past 80 years. In 
1920 tricalcium phosphate (TCP) was implanted for the first time into animals to test its 
efficacy as a bone substitute
[99]
.Hydroxyapatite (HA) was first implanted in rats and guinea 
pigs
[100]
 in 1951. During 1970s, other calcium orthophosphates were synthesized, 
characterized, investigated and tried in medicine
[101-107]
. 
Calcium phosphate cements are also referred to as calcium phosphate bone cements 
(CPBC)
[108]
considering their suitability for repair, augmentation and regeneration of bones. 
Self-setting calcium orthophosphate formulations are mixtures of amorphous and/or 
crystalline calcium orthophosphate powder(s) with an aqueous solution such as distilled water, 
phosphate-buffered saline (PBS), aqueous solutions of sodium orthophosphate (~ 0.25 M), 
orthophosphoric acid, citric acid (~ 0.5 M)
[110]
, sodium silicate
[111,112]
, magnesium hydro-
orthophosphate
[113]
 or revised simulated body fluid (rSBF)
[114]
. They show good 
bioresorbability and are considered as the second generation bone substituting 
biomaterials
[109]
. 
Biocements, in case of defects, aim at imitating the bone until a new bone has been grown 
without causing much disturbance to the bone functions and properties. Initial setting of the 
cements also provides much needed mechanical strength until recovery of the defect. Self-
setting calcium orthophosphate provides faster setting time; enhanced moldability and 
biocompatibility; and easy manipulation by incorporating additives
[115]
 such as Na
+
, K
+
, Mg
2+
, 
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Ca
2+
, Sr
2+
, H+ , PO4
3-
, HPO4
2-
, H2PO4
-
, P2O7
4-
, CO3
2-
, SO4
2-
, HSO4
-
, Cl
-
, OH
-
, F
-
, SiO4
4
. 
Setting of calcium orthophosphate cements starts with its dissolution in an aqueous medium. 
During precipitation new crystals are formed that grows and forms a web of intermingling 
microneedles or microplatelets providing mechanical strength to the cement after setting. The 
setting reaction may also occur owing to hydrolysis of metastable calcium orthophosphate in 
aqueous medium. In this case Ca/P ionic ratio could be maintained. The chemical reactions 
during setting depend on the chemical composition of the cement. 
The hydration process being slightly exothermic is beneficial for biomedical applications. This 
process undergoes five periods: initiating period, induction period, accelerating period, 
decelerating period and terminating period
[117]
.Calcium Orthophosphate Cements are 
classified as either apatite (forming HA and/or CDHA as the end product)or brushite (forming 
DCPD as the end-product) of the setting reaction. Injectability is influenced by particle size 
(smaller) and shape (spherical shape or round). Lack of cohesion in cements may prevent its 
setting. Porosity is required for good in vivo resorption of implanted materials. Calcium 
orthophosphate cements have good compressive strength
[118]
 but this value is lower than that 
of natural bones, teeth or sintered calcium orthophosphate bioceramics
[116]
. 
Self-setting calcium orthophosphate formulations have been successfully used for treatment of 
calcaneal fractures
[120]
, hip fractures
[121,122]
, augmentation of osteoporotic vertebral bodies
[123]
, 
distal radius fractures
[124]
, tibial plateau fractures
[138,124-128]
, restoration of pedicle screw 
fixation
[129,130]
, reinforcement of thoracolumbar burst fractures
[131]
, cancellous bone 
screws
[132,133]
, in wrist arthrodesis
[134]
 and for fixation of titanium implants
[135]
. In the cement 
formulations, drugs might be incorporated into both a liquid and  powder phases. Crystal 
morphology
[136]
 influences the drug delivery properties of the cements.  
Unlike CPCs, most of the other synthetic materials prepared are unable to adapt to the exact 
shape of the bone defect due to which the contact between the implant and surrounding tissues 
is not proper. It is expected that the use of self-setting calcium orthophosphate formulations 
will enable a faster recovery. These biomaterials give equal contribution to the biological and 
materials sectors. Therefore, more versatile ideas and approaches are required for its further 
development. 
Amorphous calcium orthophosphate is also referred to as ACP. Interest in ACPs arose in the 
1970s, due to their possible presence in the bone of vertebrates though it is not detectable in 
the earliest stage of tissue formation
 [86,87,88,89–94]
. The CaP phases in milk have some analogy 
with ‘pure’ ACP phases. Amorphous calcium polyphosphates contain concatenated phosphate 
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groups. ACP phases are one of the most frequent forms of CaP minerals found in biological 
organisms
[85]
. CaPs when synthesized through precipitation process generally produce ACP as 
the intermediate phase. ACP is responsible for the setting reaction in self-setting injectable 
cements.  
ACPs are considered as the reservoir of calcium and phosphate ions in many biological 
systems, for example in primitive organisms. They can be found in teeth and the exoskeletal 
structures of marine invertebrates
[90]
 abundantly. The existence of ACPs in vertebrates is 
mainly present in the inner ear structures of embryonic sharks and milk of mammals
[86,90]
. 
Recent works have shown presence of a transient amorphous mineral precursor in bone and 
teeth. Characterization of these transient amorphous mineral phases in a tissue without altering 
them by dehydration, irradiation or the use of solvents is difficult. It transforms into 
amorphous-like domains on dehydration. Whereas wet and/or poorly preserved amorphous 
phase samples containing hydrated surface forms more stable apatite or octacalcium phosphate 
(OCP) phases. 
ACPs are distinguished by their Ca/P atomic ratio. Amorphous tricalcium phosphate (ATCP) 
is formed at high temperature and has atomic Ca/P ratio of 1.5 in a pH range of 9 to 11. ACPs 
can contain HPO4
2-
 ions instead of PO4
3-
in case of acidic solutions and possess a lower Ca/P 
ratio. ACP readily converts into dicalcium phosphate dihydrate (DCPD) with lower Ca/P 
ratios of 1.15 due to its unstability. 
ACPs can be prepared either in aqueous medium at low temperature (known as wet route) or 
by using high energy processing or at high temperatures (known as dry route). Ca/P ratio of 
synthesised ACP depends these routes. The ratio may range from1 to 2 or may be even higher. 
The ACP synthesized should have a Ca/P ratio of 1.5 or 1.33. 
ACPs are used to form coatings, cements, ceramics and composites. Presence of ACP is 
sometimes controllable and sometimes uncontrollable as in plasma sprayed HA coatings. ACP 
being a resorbable cements is used for drug delivery of antibiotics or growth factors for 
orthopaedic and dental applications
 [95]
.  
The instability of ACPs restricts it from its mass production, storage and processing. Though 
its adsorption properties are not well known its ability of easy assimilation in vivo can be used 
to prepare composites with high remineralising potential or drug carriers. 
Tricalcium phosphate is available in three polymorphic forms: low-temperature form i.e., β-
TCP and the high-temperature forms i.e., α-TCP and α’-TCP. α’ is not much significant as it 
exists at temperatures >~1430 °C and reverts back to  α-TCP on cooling below the transition 
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temperature almost instantaneously. β-TCP is more stable at room temperature and transforms 
reconstructively
[49,50]
 at temperature ~1125°C to α-TCP, and can be retained during cooling to 
room temperature
[51]
. 
α- and β-TCP are currently being used in dentistry, maxillo-facial surgery and orthopaedics. 
Several commercial mono- or biphasic bioceramics and composites have β-TCP as their major 
component whereas α-TCP is the major constituent of various hydraulic bone cements[52,53]. 
α- TCP and β-TCP have different biological properties and clinical applications. This is 
because though α- TCP and β-TCP have same chemical composition, they differ in their 
structure, density and solubility. Both α- TCP and β-TCP are used in clinical operations. α-
TCP crystalline structure was related to the mineral glaserite (K3Na(SO4)2) by Dickens and 
Brown in 1972
[54]
 and later studied in detail by Mathew et al. in 1977
[55]
 and more recently by 
Yashima and Sakai
[56]. α-TCP crystallizes in monoclinic crystal system. 
Synthesis of α-TCP can be carried out by thermal transformation of a precursor with molar 
ratio of Ca:P = 1:1.5. Self-propagating high-temperature synthesis
[71]
 and combustion 
synthesis
[57–59]
 have also been employed for α-TCP synthesis. The biological behaviour of α-
TCP-based biomaterials has been studied in several in vitro
[60–64]
 and in vivo
[65–70]
 studies. α-
TCP is non toxic and non irritant on intact rabbit skin
[70]
 in solid and paste forms. New bone 
deposition was observed on the surface of α-TCP by the experimental groups and fibrous 
connective tissue was predominantly present at the centre of control sites. α-TCP is thus a 
degradable osteoconductive material, used for bone regeneration
[66]. α-TCP particles are also 
efficient drug carriers. 
Thermal transformation of β-TCP above the temperature resulting in polymorphic 
transformation of βα is the rational way to synthesize α-TCP. α-TCP is thermodynamically 
metastable at temperatures < ~1100°C but as the polymorphic transformation of βα is 
reconstructive with considerable activation energy α-TCP may be preserved at this 
temperature without quenching. α-TCP has been proposed as component of several bone 
cements since last two decades. Several granules, blocks and composites have been 
synthesized from α-TCP since then which have received growing attention as bone repairing 
materials. However, commercial α-TCP, reagent or biomedical grade, are very scarce so 
researchers and developers have to synthesize it themselves. 
CPCs are biocompatible, bioactive, osteoconductive and osteointegration
[137–139]
. Mostly CPC 
systems based on α-tricalcium phosphate (α-TCP) or tetracalcium phosphate (TTCP)[140–150] 
are studied. These systems have slow setting reactions creating problems in surgical 
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operations. Upon setting these calcium phosphates systems are converted to apatite. In apatite 
phase, the CPC crystals grow progressively and gets entangled. This renders rigidity and 
strength to the set cement. 
α-TCP hydrolyzes in water, to form calcium-deficient hydroxyapatite (CDHAp). TTCP gets 
completely converted to apatite by acid–base reaction with a neutral or acidic phosphate As 
apatitic cements are sparingly soluble under physiological conditions, their process like 
bioresorption and complete substitution by new bone are very slow. Faster setting time for the 
above CPC systems can be achieved by the addition of highly reactive calcium phosphates 
with reduced particle size and crystallinity, for example addition of amorphous calcium 
phosphate (ACP). This could also enhance the bioresorption of the resultant formulations. 
Precipitated ACP has a high specific surface area but lacks long-range periodic atomic-scale 
ordering of crystalline HA. Larger specific surface area causes faster resorption and also 
enhances osteoblast precursor cell attachment. 
During hardening of CPC-ACP cement, it is converted into nanocrystalline apatite and gets 
fully resorbed and replaced by bone after 26 weeks of implantation. Though ACP/DCPD 
cement paste does not harden at room temperature appreciably, but it hardens very fast at body 
temperature thus ensuring faster setting upon implantation. 
Addition of ACP to α-TCP and TTCP/MCPM causes surface transformations which enables 
better cell attachment than ACP-based CPC; and also modifies their microstructure forming 
smaller crystal which reduces its compressive strength. The set ACP/α-TCP-based cement 
forms nanosized needle-like particles, while the set ACP/TTCP/MCPM-based cement forms a 
dense conglomerate of nano spheres. This nanocrystalline apatite formed promotes cell 
viability and proliferation on the cement surfaces. ACP addition decreased the crystallinity of 
the end products. Further studies are required to understand the effect of surface crystal 
structure and transformation of cement surface in cell adhesion and metabolism. 
CPCs are hydraulic cements generally formed by combination of one or more calcium 
orthophosphate powders mixed with a liquid phase. Unlike conventional calcium phosphate 
ceramics, CPC has an advantage that it can harden in vivo, through a low-temperature (at 
room or body temperature)setting reaction. But due to the intrinsic porosity of CPCs, calcium 
phosphate ceramics have greater mechanical strength than it limiting its application in non- or 
moderate-load-bearing situations
[19,21]
. CPCs also lack full injectability and has slow 
resorption rate. There is not heat release during the setting reaction of CPCs. Hence, different 
drugs and biological molecules can be incorporated into them making them suitable for drug 
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delivery applications 
[20]
. CPCs have excellent bioactivity, osteoconductivity and resorbability 
(resorption rate depends on their composition and microstructure) which makes them a better 
choice as drug carriers than to acrylic bone cements and other injectable biomaterials and 
polymers. Though intrinsic porosity of CPCs lowers its mechanical strength but it allows the 
incorporation of drugs, biologically active molecules and even cells, without any thermal 
denaturalization or loss of activity during preparation or implantation. 
Efficiency of material as a drug delivery device depends upon its microstructure i.e. their 
specific surface area, permeability, tortuosity and porosity; the degradation potential of the 
matrix, the solubility of the drug and the nature of the interactions between drug and matrix. 
Usually drugs are incorporated into CPCs by (i) blending drug powder with the solid phase (ii) 
dissolving it within the liquid phase(iii) incorporation of the drug by impregnation of pre-set 
CPC solid blocks or granules with a drug solution (iv) incorporation of the drug on polymeric 
microspheres before blending with CPC. In the first two cases the drug is incorporated 
throughout the whole volume of the material, although incorporation in the liquid phase 
provides a more homogenous distribution. In the third case, hydrated compounds with high 
specific surface areas and particular microtextures that supports drug loading and release 
mechanisms can be obtained due to material consolidation by a low-temperature dissolution-
precipitation reaction though injectability is compromised in this case. In the last case of drug 
incorporation modification of the release kinetics of the drug (limiting burst release) can be 
done. Moreover in this case the degradation of the microspheres creates a porous matrix that 
can enhance resorption and remodeling capability.  
The addition of a drug can modify the clinically relevant properties of CPCs like its setting 
kinetics, rheological properties, mechanical properties and microstructural development. 
Distribution of the drug within the CPC determines its drug release kinetics. When the drug is 
incorporated in the powder phase of the CPC, partial dissolution of the drug particles takes 
place. This depends on the solubility of the drug in the reactant liquid phase of the CPC. 
Several works have dealt with the incorporation of different active principles namely low 
molecular weight drugs, high molecular weight biomolecules and ions; that aim at achieving 
local and controlled delivery to bone or dental sites. 
To allow a more systematic study it is desirable to improve the homogeneity of the methods 
evaluating release and in-depth study of the release mechanisms. 
Many discoveries and developments have been made in the field of CPCs starting from 
calcium silicate and sulphate based cements in the construction industry to poly(methyl 
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methacrylate) medical cements. Basic properties of CPCs such as setting time, injectability 
and cohesion require further research. 
It is known that certain factors such as (i) powder size (smaller size-shorter setting time), (ii) 
amount of liquid (smaller amount-shorter setting time), (iii) by addition of rapidly available 
calcium can modify the setting time of the cement. 
Despite the numerous publications, further research is required to understand the basic 
properties of the cements such as setting time, fracture mechanics like effect of microporosity 
and fatigue properties; and cohesion. 
A new milling method of synthesis for amorphous calcium phosphates have recently been 
proposed
[23,24]
 which can more effectively control setting reactions and thus can support better 
drug delivery systems. Moreover such synthesized CPCs can further be used to synthesise 
calcium phosphate granules and porous blocks having very high surface areas that are 
biologically very reactive and can be potent drug carriers. Still there remains a large gap 
between cement development and its clinical use. 
Cement developing engineers or CPC researchers are more interested in improving the 
performance of CPC by studying and modifying its chemical and physical properties. Whereas 
clinicians are interested in a CPC that ‘works’, regardless of the composition. A ‘working’ 
cement should have low price, easy and reliable mixing and delivery, good visualisation 
during injection (e.g. for vertebroplasty) and faster replacement with bone or rapid bone 
apposition. 
CPC has poor injectability compared to PMMA cements. Recent research of cement 
injectability have enabled a better understanding of CPC injectability
[25]
 and have also 
provided innovative solutions
[26,27]
 such as cheaper alternatives to the use of rheological agents 
such as sodium hyaluronate or chondroitin sulphate. 
Earlier works showed that brushite CPC had a faster rate of resorption than apatite CPC
[22]
. 
However, in vivo transformation of brushite into apatite
[28]
, impairs its resorption rate. This 
transformation can be delayed by the addition of a soluble magnesium salt. Apatite CPC 
resorption rate can also be increased by incorporation of macropores in the structure. This also 
results in higher volume of bone ingrowth.  
The rheological behaviour of CPC is largely unknown. Temperature has a great impact on the 
setting properties of CPC. The setting time of apatite can be reduced by three- to four times by 
increasing the temperature from 20 to 37°C. Also, addition of radio-opacifiers into CPC gives 
better visuality during injection though solutions are not trivial. Recent and future 
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developments will reduce the gap between CPC research and clinical and enable better 
commercialisation of more varied products that possess better clinical properties and hence 
improve patient life quality. 
Bone substitution materials are required when the natural regeneration process of bone fails to 
heal the acquired or congenital defects due to its critical size. These materials aid in healing 
process and work as a substitute for the missing bone providing mechanical and structural 
support to it. Calcium phosphate cements (CPCs) are used clinically as valuable bone 
substitution biomaterials for over 20 years
[72]
. Paste of Calcium phosphate salts in an aqueous 
solution is prepared. This paste transforms into either brushite or apatite as their final product 
upon setting depending on the composition of starting materials
 [73]
. Hydroxyapatite is much 
similar to the natural bone mineral phase. Thus HA-forming compositions of CPCs show good 
biocompatibility, osteoconductivity and resorbility in vivo
[74–75]
.  
Injectability
[72,76]
 is a major property required in case of minimal invasive applications, such as 
spinal applications, vertebroplasty, void filling and reinforcement of osteoporotic bone. This 
arises the need to study the consistency and cohesive properties. Conventional CPC powder 
mixed with a liquid phase causes intrinsic problems in handling as the paste needs to be 
prepared just before implantation and the prepared cement also starts immediately after 
mixing . Properties also change continuously during this working phase. The surgeon thus has 
very less time for preparation and application of CPC which again is affected by changes in 
environmental conditions resulting in degraded mechanical strength and inhomogeneity 
causing unexpected clinically relevant failures
 [77,78]
. 
To overcome the above problems, ready-to-use cements were developed taking a single phase 
calcium phosphate powder or a mixture of several calcium phosphate powder of both brushite 
and apatite phases
[79]
. Ready-to-use cements are prepared by stabilizing the different calcium 
phosphate reactants with separate liquid or pasty components. In this setting reactions of the 
cement is initiated by the component that contains an aqueous liquid. The preparation process 
is faster than conventional CPCs as two liquid phases can be mixed more homogeneously than 
powder with liquid. In this dual chamber syringes equipped with a mixing device are used 
which has a few advantages i.e., reduced time requirement for paste preparation, less risk of 
contamination, enhanced reproducibility and immediate injection of the mixture in the 
defective tissue. Ready-to-use cements can also be prepared by the use of water-miscible non-
aqueous liquids like glycerine 
[80]
 or polyethylene glycol (PEG)
[81]
. Miscibility with water and 
biocompatibility of the components are important for such systems
 [78]
. In such cases pre-
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mixed paste are prepared under defined conditions and can be stored until use. This is because 
powder and liquid are not in contact and are mixed during surgery thus retaining the adjusted 
viscosity and provides longer injection time for the surgeon as the cement setting starts when 
it is delivered to the aqueous environment of the defect site 
[81–83]
. The α-TCP based CPC 
formulation of Biocement D
[84] 
was used as principal cement component for the development 
of ready to use cement formulation. The paste-CPC was injectable, had better cohesion 
properties, better compressive strength and longer shelf life compared to conventional pl-CPC 
of similar cement composition. The final product formed from the setting reaction was found 
to be nanocrystalline HA as in powder/liquid CPC. This concept provides a choice to mix the 
CPC paste with aqueous components that may contain drugs or biological components or 
autologous biological fluids like blood or bone marrow aspirate. Thus ready-to-use paste-CPC 
opens new opportunities for simplified filling of bone defects and augmentation of 
osteosynthetic defects. 
As discussed earlier that despite its favourable bone bonding properties, calcium phosphates 
exhibits poor mechanical strength restricting its use in non-load bearing defects
[30]
 or in pure 
compression loading
[29]
. Enhancement of the mechanical properties can be achieved by 
forming CPC composite materials either with polymers that interpenetrate the porous matrix 
or with fibrous reinforcements
[33] 
thus extending the applicability of calcium phosphates
[33]
.  
Calcium phosphate composites formed by addition of polymers have been extensively 
reviewed by several authors (e.g. 
[30,34,35]
).Reinforcement of brittle CPC with fibers
[33]
 
particularly toughening by long continuous fibers
[37]
 is one of the most successful approaches 
in enhancing its mechanical behavior. Brittle materials suffer a sudden failure without any 
significant preceding plastic deformation. Thus work needed to induce failure and fracture 
deformation is less. 
Macroscopic behaviour of FRCPC is a combined result of strength and stiffness of both fiber 
and cementitious matrix, matrix toughness, mechanical interaction between fibers and matrix 
and supplementary effects of polymeric additives or aggregates. Apart from material strength, 
materials show different behavior in case of two aspects (i) strain to failure (ii) the area below 
the curves which is a measure of energy necessary to yield material failure. Both properties 
increase in the order of their failure modes i.e., brittle < tension softening (quasi-brittle 
materials) < strain hardening (pseudo strain hardening; highly ductile materials). 
In case of pure brittle failure immediate fracture occurs in which ahigh amount of energy is 
absorbed due to fracture of fiber reinforced cementitious composites. The strain to failure is 
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also higher in this case. Quasi-brittle composites show tension softening behavior. Here fiber 
bridging in the single crack opening dissipates fracture energy and delays the fracture into 
pieces. Peak load here results in fracture of the matrix thus the composite fails to carry any 
substantial load further when peak load is reached. Most desirable behavior for fiber 
reinforced composites i.e., ductility can be achieved with (pseudo) strain-hardening behavior. 
It can bear even more load after initial matrix cracking. Here a network of multiple cracks is 
formed thus dissipating more energy in the fracture process
[38,39]
. Fibers influence the fracture 
processes ahead of a crack tip in the frontal process zone (FPZ)
[40]
, behind the crack tip in the 
crack bridging wake
[41]
 and adjacent to the crack plane
[42]
. 
In a monolithic CPC, catastrophic failure occurs due to fast crack propagation from the initial 
crack
[33]
. In fiber reinforced composites depicting quasi-brittle behavior, the linear elastic 
region ends with the first cracking of the matrix. Behaviour of the FPZ determines the first 
crack strength of the composite
[40]
. The material softens as the crack propagates. High ductility 
of the fiber reinforced cement results in its high bending capacity. It is a frequently observed 
trend in FRCPC research
[31,36,45,48]
 that strength and ductility of the composites increases with 
fiber content. Injectability of CPC is required for its accessibility onto narrow cavities 
[46,47]
. 
Viscosities of short fiber reinforced CPC is low enabling needle injection of the fiber-cement 
paste. Such composites are claimed to be isotropic in their properties
[49]
. The use of woven 
fibers
[31,43,44]
 has been less common and provides  anisotropic reinforcement. Fiber reinforced 
calcium phosphate cements (FRCPC) area newly developed class of biomedical materials in 
which hydroxyapatite is generally reinforced with different fiber materials to overcome the 
brittle fracture behavior of conventional CPC by ductilization. The reported increase in 
toughness (work of fracture) between FRCPC and CPC reaches two orders of magnitude. 
In the present work we have studied the reinforcement of Silicon doped alpha tricalcium 
phosphate by addition of e-glass fiber. E-Glass fiber is a bioinert material. Though silicon 
addition suppose to increase the bioactivity but it decreases the mechanical strength of the 
cement. Without compromising the bioactivity of silicon, our objective is to enhance the 
mechanical strength of Si doped α-TCP by addition of 10 weight% e-glass fiber which can 
arrest the crack, deflect the crack and increase the fracture toughness as well as mechanical 
strength. 
 
Objective:: To study the effect of Si doping and e-glass fiber addition on physicochemical 
and mechanical properties of calcium phosphate cement. 
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3. EXPERIMENTAL PROCEDURE 
 
 
3.1  Materials   
 
3.1.1  CaCO3 as Calcium source 
Molecular weight = 100gm 
Density = 2.71 g/cm³ 
Company = Vico Trading and Production Co., Ltd - Vietnam  
 
3.1.2  CaHPO4 as Phosphorus source 
Molecular weight = 136.06gm 
Density = 2.93 g/cm³ 
Company = Sigma-Aldrich Co., India 
 
3.1.3  TEOS as Silicon source 
Molecular weight = 208.33gm 
Density = 940.00 kg/m³ 
Company = TEOS Powertrain Engineering, Trappes 
 
3.1.4  HNa2O4P for preparation of cement liquid 
Molecular weight = 141.98gm 
Density = 1.679 g/cm³ 
Company = Shanghai Orgpharma Chemical Co.,Ltd, China 
 
3.1.5  e-glass fiber for reinforcement 
Tensile strength
[96]
 = 3445 MPa 
Compressive strength = 1080 MPa 
Density = 2.58 g/cm
3 
Thermal expansion = 5.4 μm/m.°C 
Softening temperature = 846°C 
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3.1.6  Reagents for ion concerntration in SBF 
 
NaCl(99.5%)as source of Na
+
 and Cl
-
 
Molecular weight = 58.44 g/mol 
Density = 2.16 g/cm³ 
Company = Merck, Germany 
 
NaHCO3(99.5%) as source of  HCO3
-
 
Molecular weight = 84.007 g/mol 
Density = 2.20 g/cm³ 
Company = Merck, Germany 
 
KCl(99.0%) as source of  K
+
and Cl
-
 
Molecular weight = 74.5513 g/mol
 
Density = 1.98 g/cm³ 
Company = Merck, Germany 
 
MgCl2.6H2O(99.0%)as source of  Mg
2+ 
Molecular weight = 95.211 g/mol 
Density = 2.32 g/cm³ 
Company = Merck, Germany 
 
CaCl2.2H2O(99.0%)as source of  Ca
2+ 
Molecular weight = 147.0146 g/mol 
Density = 1.85 g/cm
3
 
Company = Merck, Germany 
 
Na2HPO4.2H2O(99.5%)as source of  HPO4
2- 
Molecular weight = 301.9330 g/mol 
Density = 1.7 g/cm3 
Company = Merck, Germany 
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Na2SO4 as source of  SO4
2- 
Molecular weight = 142.04 g/mol 
Density = 2.66 g/cm³ 
Company = Merck, Germany 
 
(CH2OH)3CNH2 as buffer 
Molecular weight =  121.1356 g/mol 
Density = 0.84 g/ml 
Company = Angus Chemical Company, Buffalo Grove, IL, US 
 
HCl (37 vol%) for H
+ 
ion
 
Molecular weight = 36.5 g/mol 
Density = 1.48 g/ml 
Company = Carlo-Erba, Rome, Italy 
 
3.2 Methods 
 
3.2.1 Synthesis of Alpha Tricalcium Phosphate 
At first hydrated di-calcium phosphate (DCPD having molecular mass=172.09gm) was heated 
at 180
0
C for 4hours to convert it to DCPA. Then calcium hydrogen phosphate (CaHPO4having 
molecular mass=136.06gm) and calcium carbonate(CaCO3 having molecular mass=100gm) 
were taken in the molar ratio of 2:1 ie.,27.2gm of di-calcium phosphate anhydrous (DCPA) 
and 10gm of CaCO3. Then the required amounts of DCPA and CaCO3 were ball milled in iso-
1-propanol for 12 hours for uniform mixing. After milling the sample was collected and dried. 
The dried sample was then crushed to powder and was sintered at 1300°C for a period of 4 
hours. This was followed by rapid air quenching of the samples. After sintering the sample 
was ground and sieved to obtain a particle size of 38μm. 
3.2.2 Synthesis of 1mol% Silicon doped Alpha Tricalcium Phosphate 
In this process tri-ethyl orthosilicate solution (TEOS having molecular mass=208.33gm) was 
taken for silicon doping of Alpha Tricalcium Phosphate.Calcium hydrogen phosphate 
(CaHPO4having molecular mass=136.06gm) and calcium carbonate (CaCO3 having molecular 
mass=100gm) were taken in the molar ratio of 2:1 ie.,27.2gm of di-calcium phosphate 
anhydrous (DCPA) and 10gm of CaCO3for the preparation of Si doped α-TCP. Di-calcium 
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phosphate (DCPD having molecular mass=172.09gm) was heated at 180
0
C for 4hours to 
convert it to DCPA. About 12drops of TEOS (0.1166gm=0.1249ml)was then added to the 
mixture of DCPA and CaCO3. Then ball milling of the required amounts of DCPA and CaCO3 
were done in iso-1-propanol for 12 hours for uniform mixing. After milling the sample was 
collected and dried. The dried sample was then crushed to powder and then sintering was done 
firstly at 1100°C for 2 hours and then at 1300°C for a period of 4 hours. This was followed by 
Rapid Air quenching of the sample. This was followed by ball milling of the quenched sample 
for 24 hours to obtain a particle size below 25 μm. 
3.2.3   Preparation of anhydrous sodium hydrogen phosphate solution 
Required amount of HNa2O4P (having formula mass= 141.98 and density= 1.7gm/cc) were 
mixed with distilled water to prepare 2vol% and 5vol% solutions of sodium hydrogen 
phosphate. 
 
3.2.4   Preparation of SBF solution 
Simulated Body Fluid was prepared by the standard Kokubo-Method. 
 
Table1: Chemical composition of SBF solutions
[97] 
 
Order 
 
Reagent 
 
Amount (gpl) 
1 NaCl 6.547 
2 NaHCO3 2.268 
3 KCl 0.373 
4 Na2HPO4.2H2O 0.178 
5 MgCl2.6H2O 0.305 
6 CaCl2.2H2O 0.368 
7 Na2SO4 0.071 
8 (CH2OH)3CNH2 6.057 
9 HCl 40mL 
 
3.2.5 Study of hardening and setting of CPC from α-TCP and Si doped α-TCP powders 
Weighed amounts of TCP powder and measured amount of sodium hydrogen phosphate 
solution were taken. The Powder to liquid ratio is predetermined and was maintained at 
3:1.After that the calcium orthophosphate powder(s) and the sodium hydrogen phosphate 
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solution were mixed together to form a viscous and moldable paste that sets into a firm mass 
within a few minutes.  When the paste becomes sufficiently stiff, it was introduced into the 
mould. The paste inside the moulds was then allowed to set in a 100% humid environment by 
covering it with wet tissue papers inside the incubator. After about 3hours of setting the set 
samples were removed from the moulds and immersed in SBF solution prepared by procedure 
3.2.4. 
3.2.6 Study of hardening and setting of 10 wt% E-glass fiber reinforced CPC  
E-glass fibers were immersed in SBF solution for about 6-7 days so that the fibers gets coated 
with hydroxyapatite. Hydroxyapatite coating on the e-glass fiber helps in better bonding of the 
fibers and calcium phosphate powder after setting as it provides better entanglement of the 
hydroxyapatite particles formed on CPC to that of the hydroxyapatite coating on the e-glass 
fiber. Then a batch of Si doped α-TCP powder and glass fiber was prepared by proper and 
uniform mixing of e-glass fiber (10% by weight of powder taken) and Si doped α-TCP 
powder. The batch thus prepared was then made to set according to the process followed in 
procedure 3.2.5 
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4. CHARACTERIZATION 
 
4.1 XRD Analysis:: 
X-ray diffraction analysis of the α-Tricalcium phosphate and Si doped α-Tricalcium phosphate 
powders and the fully set cements at periodic time intervals were performed by using Rigaku 
Ultima IV operated at 40KV voltage and 40 mA current at room temperature. Data were 
collected by using  solid state detector Cu as target with scanning range of 2θ=10°–70°,and a 
2θ step size of 5°/min. 
The reference number of the compound formed was found from the literature and matched 
using PCPDF WIN program. XRD analysis of the powder samples was performed using the 
X’PERT HIGH SCORE software. 
 
4.2  Hardening and Setting::  
Self-setting calcium orthophosphate formulations were formed by mixing amorphous and/or 
crystalline calcium orthophosphate powder(s) with a 5 vol% aqueous solution of sodium 
hydrogen phosphate. After the calcium orthophosphate powder(s) and the solution are mixed 
together, a viscous and mouldable paste is formed that sets to a firm mass within a few 
minutes.  E-Glass fibers were also added wherever applicable. Then the set cement samples 
were removed from the moulds and are immersed into the SBF solution. 
Initial (I) and final (F) setting times were measured using the  Vicat needle (ASTM, C191). A 
ring with a diameter of 20 mm and a height of 10 mm were used as mould. All measurements 
were performed at room temperature. The setting times were obtained from a set of three 
samples each of α-Tricalcium phosphate and Si doped α-Tricalcium phosphate cement. 
 
4.3  Study of kinetics of setting reaction in CPC 
Samples of set cement were removed from the mould and immersed in SBF at 37 °C for 10 
days. At intervals of 0 hour, 10 hour, 1 day, 2day upto 10 days the immersed samples were 
removed from the SBF solution. The samples were then crushed to powder and immersed into 
acetone to stop the hydraulic setting reaction. Putting the samples onto acetone arrests theα-
TCP to HA conversion reaction at that point. This aids in determining the conversion rate of 
the reaction.  
After drying in air (to remove acetone), the sample pieces were milled under 70 μm, and the 
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X-ray diffraction patterns were obtained from 2θ = 10°-70° at a step size of 20°/minute. α-
TCP exhibits a peak of 2.905 at plane (170). Hydroxyapatite has a peak of 2.814 at plane 
(211). 
The extent of conversion of α-TCP into HA was calculated using the following equation: 
 
Conv.= [(I0/Is)-(It/Is)]/[(I0/Is)-(I∞/Is)] 
where, 
I0 = integrated intensity of the peaks corresponding to the converted phase at the beginning                                       
It = integrated intensity of the peaks corresponding to the converted phase at time t 
I∞ = integrated intensity of the peaks corresponding to the converted phase at infinite time                                                 
Is = integrated intensity of the peak corresponding to the internal standard.  
 
4.4  Determination of Mechanical Strength::  
The set CPC in moulds were immersed in SBF solution at 37.5°C. Samples were then 
removed  from SBF at periodic time intervals for use as test specimens and compression tested 
in Tinius Olsen H10KS Universal Testing Machine. Load was applied at a speed of 1mm/min 
at room temperature until failure. Three replicas of each cement (α-TCP, 1% Si doped α-TCP 
without e-glass fiber, 1% Si doped α-TCP with e-glass fiber) formulations were tested. 
Diametral Tensile Strength is calculated using the formula:: 
 
DTS= 2σ/ Πdt 
where, 
σ = Load in Newton 
Π = constant (3.14) 
d = diameter of the samples 
t = thickness of the samples 
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4.5  Analysis of microstructure using Scanning Electron Microscopy::  
The samples were  taken out from SBF after definite time interval and dried in air. Then a 
3minutesurface coating of graphite was applied to the samples. Graphite coating makes the 
surface of the samples conductive. This aids in better examination of the surface (fractured 
surface). The samples were then analyzed by means of scanning electron microscopy (NOVA 
NANO SEM FEG operated at voltage of 310V and 90µA current) to observe its 
microstructure. 
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5. RESULTS AND DISCUSSION 
 
5.1 Phase evaluation  of synthesized powder 
The x-ray diffraction patterns of undoped α-TCP and 1 mol% Si doped α-TCP powders  
revealed the presence of α -TCP as major phase with traces of  β-TCP formed during the 
quenching process. 
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Fig.2 (a)  XRD pattern of undoped α-Tricalcium Phosphate 
Figure 2 (a) shows the diffraction pattern of α-TCP powder synthesized using solid state 
reaction of calcium carbonate and anhydrous di-calcium phosphate at 1300˚C for 6 hours. 
Major phase of α-TCP with trace amount of β-TCP was observed in the XRD pattern. 
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β-TCP was expected to transform into α-TCP beyond 1125˚C but the α-TCP phase being a 
metastable phase some amount of β-TCP was formed during the cooling of the powder. 
Our major objective was to maximize the amount of α-TCP phase in the synthesized powder 
so that enhanced hydrolysis reaction of α-TCP into hydroxyapatite can occur during the 
setting of the cement in simulated body fluid (SBF). 
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Fig.2 (b) XRD pattern of 1 mol% Si doped α-Tricalcium Phosphate 
X-ray diffraction pattern of 1 mol% Si doped α-TCP powders is shown in figure 2 (b). Almost 
similar type of phase composition as that in undoped -TCP was found in the XRD pattern of 
Si doped -TCP. 
 
5.2  Composition of E- glass fibre 
EDAX analysis of the procured E-Glass fibre is shown in figure 3 and the elemental 
composition is given in table 3. The presence of Al2O3 in the silica glass fibre gives necessary 
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mechanical strength to E- glass fibre. 
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Fig. 3. EDAX analysis of E- glass fiber 
 
Table 2: Quantitative analysis of E- glass fibre from EDAX data 
Element Atomic No. 
 
Weight% 
 
O 8 50.26% 
Ca 20 16.2% 
C 6 - 
Si 14 26.04% 
Al 13 7.4% 
 
Figure 4 shows image of E-Glass fibres obtained through scanning electron microscopy. E- 
glass fibres having an average diameter of 14 m and length of 1.2-1.6 mm were mixed to the 
extent of 10 wt% with Si-TCP, kneaded, formulated like a paste, hardened in SBF and the 
physicochemical and mechanical strength of the resulted CPC were evaluated.  
29 
 
 
Fig.4 FESEM micrograph of E- glass fiber 
 
5.3  Setting Time 
Setting time of calcium phosphate cement was observed at a powder to liquid ratio of 1:3 
using Vicat Needle. α-tricalcium phosphate cement exhibited an initial setting time of about 
10 minutes and final setting time of 25 minutes, while 1% Si doped α-TCP cement showed an 
initial setting time of about 14 minutes and took 35 minutes for its final setting. Si doped 
calcium phosphate cement showed a delayed initial and final setting time as compared to 
undoped calcium phosphate cement because of retarded rate of hydrolysis and HA crystal 
growth in Si-doped α-Tri-calcium Phosphate into hydroxyapatite as compared to undoped α-
Tri-calcium Phosphate. CPCs set as a result of a dissolution and precipitation process
[98]
. The 
entanglement of the precipitated crystals is responsible for cement hardening unlike acrylic 
bone cements, which harden due to polymerization reaction.  
 
5.4  Kinetics of conversion into HA 
The intensities of the α-TCP peaks at 22.2° (201) and 24.1° (161,-331) decreased when the 
time of immersion in SBF rose from 5 hr to 10 days, due to its transformation into HA. Si 
doped CPC showed little slower rate of conversion into HA phase as compared to undoped 
CPC. Si doped TCP cements presented a faster initial reaction than pure α-TCP but a 
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slower secondary reaction. 
Figure 5.1 and figure 5.2 demonstrates the XRD patterns of the calcium phosphate cement 
derived from hydrolysis of α-TCP in SBF solutions at different time periods upto 10 days. 
From the XRD pattern it is evident that the increasing amount of hydroxyapatite phase is 
evolved due to hydrolysis of α-TCP into HA with increase in immersion time in SBF. 
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 Fig. 5.1  XRD pattern of undoped CPC in SBF 
XRD pattern of the α-TCP powder (a) as synthesized (b) after 0 hours of immersion in SBF 
(c) after 10 hours of immersion in SBF (d) after  1 day of immersion in SBF (e) after 2 days of 
immersion in SBF (f) after 3 days of immersion in SBF (g) after 4 days of immersion in SBF 
(h) after 5 days of immersion in SBF (i) after 6 days of immersion in SBF (j) after 7 days of 
immersion in SBF (k) after 8 days of immersion in SBF (l) after 9 days of immersion in SBF 
(m) after 10 days of immersion in SBF 
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Fig. 5.2 XRD pattern of undoped CPC in SBF with 2 varying from 21-25o. 
Figure 6.1 and figure 6.2 demonstrates the change in XRD patterns of 1% silicon doped of 
calcium phosphate cement due to hydrolysis of Si doped α-TCP in SBF solutions for different 
time durations. From the XRD pattern it is evident that there is an appearance of 
hydroxyapatite peak with disappearing α-TCP peak with increase in immersion time in SBF. 
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 Fig. 6.1 XRD pattern of Si doped CPC in SBF 
XRD pattern of the 1% Si doped α-TCP powder (a) as synthesized (b) after 0 hours of 
immersion in SBF (c) after 10 hours of immersion in SBF (d) after  1 day of immersion in 
SBF (e) after 2 days of immersion in SBF (f) after 3 days of immersion in SBF (g) after 4 days 
of immersion in SBF (h) after 5 days of immersion in SBF (i) after 6 days of immersion in 
SBF (j) after 7 days of immersion in SBF (k) after 8 days of immersion in SBF (l) after 9 days 
of immersion in SBF (m) after 10 days of immersion in SBF. 
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Fig. 6.2 XRD pattern of Si doped CPC in SBF with 2 varying from 21-25o. 
 
Figure 7 shows that throughout the time period of immersion Si-doped α-TCP cement showed 
a slower rate of conversion into hydroxyapatite as compared to undoped α-TCP calcium 
phosphate cement because Silicon retards the hydrolysis of tri-calcium phosphate into 
hydroxyapatite. 
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Fig. 7. Comparison of conversion rate of undoped and Si doped CPC  
In figure 7, (a) is for undoped α-TCP and (b) for 1% Si doped α-TCP cement. 
5.5  SEM:: 
Scanning Electron Microscopy examination of the fully set cements soaked in SBF for 10 
days at 37°C showed the formation of a thin and dense bonelike apatite layer on their surface. 
The newly formed apatite layer consisted of nodules of crystal platelets grown together, 
forming a compact layer. The examination with SEM of the set cement showed a network of 
entangled plate-like apatite crystals grown from the α-TCP grains. Typical Hadley grains 
could be observed showing an empty thick shell of hydration products inside which a α-TCP 
grain had fully reacted. Si doped CPC showed thicker and denser apatite formation as 
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compared to undoped CPC indicating its higher bioactivity. 
Figure 8 shows that the growth of flower-like hydroxyapatite crystals over the fracture surface 
of α-TCP derived cement upon its soaking in SBF solution. These crystals were mostly 
elongated. The acicular structure aids in better entanglement of crystals and formed a compact 
microstructure. 
 
Fig. 8. FESEM micrograph of undoped CPC 
 
Fig. 9.1: FESEM micrograph of Si doped CPC 
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Fig. 9.2: EDAX analysis of Si doped CPC 
 
Figure 9.1 shows the microstructure of Si doped CPC after immersion in SBF for 10 days.  
EDAX analysis of the part of microstructure in figure 9.1 confirming the presence of different 
constituent elements present in  Si doped α-TCP cement is shown in figure 9.2. 
 
Table 3: Quantitative analysis of 1 mol% Si doped CPC from EDAX data 
Element Atomic No. 
 
Weight% 
 
Ca 20 45.56% 
P 15 26.94% 
O 8 23.76% 
Si 14 1.05% 
C 6 2.67% 
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Fig. 10. FESEM micrograph of 1% Si doped CPC without e-glass fiber 
 
Figure 10 shows the growth of spherical HA crystals in Si doped CPC. Here the 
hydroxyapatite crystals were larger in size and more spherical in morphology as compared to 
undoped CPC. More voids were present in Si doped α-TCP microstructure with lesser 
entanglement of hydroxyapatite crystals than undoped α-TCP cement due retarded rate of 
hydrolysis and slower rate of HA crystal growth in Si doped CPC. 
 
Figure 11 shows the unmodified surface of E-Glass fiber before immersing it into SBF. It 
could be observed that there was no apatite growth over the surface before immersion. 
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Fig. 11. FESEM Micrograph of E-Glass fiber before immersion into SBF 
 
Fig. 12. FESEM Micrograph of E-Glass fiber after immersion into SBF 
 
The SEM analysis of the e-glass fibres in figure 12 showed the growth of apatite layer over it 
and depicts the modified surface of E-Glass fiber caused by immersing it into the SBF 
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solution. A layer of apatite crystal growth could be observed over the fiber surface. The 
deposition of apatite layer on the surface of E-glass fibre could aid in seeding of HA crystal 
during setting reaction of CPC and form a better and stronger interface between glass fibres 
and CPC crystals. 
 
5.5  Analysis of mechanical  strength: 
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Fig. 13. Comparison of DTS of doped and undoped CPCs (a) α-TCP, (b)1% Si doped α-TCP 
with 10 weight% e-glass fiber, (c)1% Si doped α-TCP. 
 
Figure 13 shows the variation of diametral tensile strength with increase in soaking time of 
SBF for undoped CPC, 1% Si doped CPC, and 10 weight% E-Glass fiber added  Si doped 
CPC. In all the cases it could be seen that with increase in soaking time in SBF, DTS for CPC 
increased due to more amount of HA crystal growth and as a result of entanglement of HA 
crystals with each other to reduce porosity and compactness in the microstructure. HA crystal 
growth and more entanglement of crystals in the pores of the microstructure gave better 
compactness with increase in elapsed time in SBF. As evident from the microstructure higher 
amount of macro porosity and lower amount of compactness of Si-doped CPC  resulted in 
lower DTS as compared to undoped CPC. 
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The plots of  load vs extension  of some of the CPC samples are shown below. 
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Fig. 14a: Load vs extension graph of undoped CPC 
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Fig. 14b: Load vs extension graph of  Si doped CPC 
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Fig. 14(c):  Load vs extension graph of 10 wt% E –glass fiber reinforced Si doped CPC 
Figure 14(a) shows the load vs entension graph of undoped CPC and  the load vs entension 
graph of Si doped CPC and e-glass fiber reinforced Si doped CPC are shown in figure  14 (b) 
and (c) respectively. In 14(b) catastrophic failure can be observed but in figure 14(c), it could 
be observed that the  glass fibers arrested and deflected the crack before failure. 
 
 
Fig. 15. Fracture surface of 10 wt% E- glass fiber reinforced 1 mol% Si doped CPC. 
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 Figure 15. shows the fracture surface  of fibre reinforced Si-doped CPC and as could be 
observed that addition of 10 weight% of E-glass fibre to Si-doped CPC filled up the voids in 
the microstructure  as well as caused crack deflection to direct inter fiber crack propagation to 
enhace strength in the composite structure. Also, as evident from the micrograph the growth of 
apatite crystal on the surface of E-glass fiber could provide stronger interface between glass 
fiber and CPC crystal and also gave better entanglement between the apatite crystals grown in 
set CPC grains. 
HA crystal grew and provided more entanglement of crystals in the pores of the 
microstructure to give better compactness with increase in elapsed time in SBF. The lower 
porosity and greater compactness in the microstructure attributes to greater diametral tensile 
strength (DTS) values observed in undoped CPC. Another possible explanation of the 
decrease of strength in Si doped CPC could be the early dissolution of the cement. 
Addition of 10 weight% of E-glass fiber to Si-doped α-TCP caused an increase in DTS value 
because fiber can fill up the voids in the microstructure as well as it can arrest and deflect the 
crack under diametral tensile stress and increase the strength. Silicon was added to CPC 
because silicon can increase the bioactivity of the set-cement but at the same time there was 
decrease in mechanical strength due to silicon addition. This can be compensated by addition 
of some amount of E-Glass fiber without compromising on its bioactivity. 
E-Glass fiber surface is modified with apatite crystal by immersing it into the SBF solution so 
that the hydroxyapatite crystal generated from the hydrolysis of calcium phosphate cement can 
easily grow on the top of the apatite layer on the E-Glass fiber and make a strong interface and 
good compactness in the microstructure. 
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6. CONCLUSIONS 
 
Effect of Si doping on the properties of α-TCP based calcium phosphate cement was 
investigated.  Doping with Si up to 1 mol%  delayed the initial and final setting time of CPC. 
Si doped CPC exhibited a little slower rate of conversion into HA phase than that of undoped 
CPC. Diametral tensile strength of both doped and undoped cement increased with increase in 
elapsed time of CPC in SBF upto 10 days.  Undoped CPC showed higher average diametral 
tensile strength than 1 mol% Si doped CPC at all time points in SBF though incorporation of 1 
mol% Si in the cement is supposed to increase its bioactivity. The objective of the present 
research was to enhance the mechanical strength of Si- doped CPC without compromising on 
its enhanced bioactivity. Addition of 10 weight percent e-glass fibre onto 1mol% Si doped 
alpha tricalcium phosphate resulted in almost 1.5 times increase in average diametral tensile 
strength of CPC. 
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